source
- Early-stage data show promise for targeting Wnt/β-catenin pathway across cancersEarly-stage clinical results from the company and several peers indicate that the Wnt/β-catenin signaling pathway could become a viable target for treating a range of tumor types. The pathway has…
- AstraZeneca launches $1.5 billion cost-saving plan to fund growth, says no layoffs expectedAstraZeneca announced a three-year cost‑saving initiative worth $1.5 billion during its third‑quarter earnings call. The program, called Reshaping for Sustainable Growth, aims to redeploy resource…